SCHEMBL21165173

SCHEMBL21165173

Cc1cc(C(O)CN(C)C)c(C)n1-c1ccc(F)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.47
SMN1; SMN2 Q16637 6/20 0.45
KDM4E B2RXH2 5/20 0.41
USP14 P54578 2/20 0.41
USP7 Q93009 1/20 0.41
NPC1 O15118 5/20 0.41
RAB9A P51151 5/20 0.41
HPGD P15428 3/20 0.41
USP5 P45974 1/20 0.41
ALDH1A1 P00352 2/20 0.40
TSHR P16473 2/20 0.39
MAPK1 P28482 1/20 0.39
POLB P06746 1/20 0.38
MAPT P10636 1/20 0.38
AOC3 Q16853 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
GAA P10253 1/20 0.38
PTGS2 P35354 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19749173 0.88 NOTUM (0.44) NOTUMSMN1; SMN2KDM4EUSP14USP7
SCHEMBL6921452 0.77 USP14 (0.56) NOTUMSMN1; SMN2KDM4EUSP14USP7
SCHEMBL18482772 0.76 NOTUM (0.53) NOTUMSMN1; SMN2KDM4EUSP14USP7
SCHEMBL23559540 0.75 SMN1; SMN2 (0.49) NOTUMSMN1; SMN2KDM4EUSP14USP7
SCHEMBL21479704 0.74 ALDH1A1 (0.47) NOTUMSMN1; SMN2KDM4EUSP14USP7
SCHEMBL23559501 0.74 SMN1; SMN2 (0.48) NOTUMSMN1; SMN2KDM4EUSP14USP7
SCHEMBL21479769 0.73 SMN1; SMN2 (0.47) NOTUMSMN1; SMN2KDM4EUSP14USP7
SCHEMBL6921657 0.72 NOTUM (0.65) NOTUMSMN1; SMN2KDM4EUSP14USP7
SCHEMBL1205131 0.68 AOC3 (0.72) KDM4EAOC3
SCHEMBL18483232 0.68 NOTUM (0.59) NOTUMSMN1; SMN2KDM4EUSP14USP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10351568-B2 Compositions and methods for enhancing proteasome activity PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2019-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10351568-B2 Compositions and methods for enhancing proteasome activity PSMG3, PSME3, PSMB11 NOTUM 2331/4885SMN1; SMN2 307/4885KDM4E 2300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.